Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 25,000 shares at $20.83 ($521K) on 2025-03-17, disclosed to the SEC on 2025-03-19.
Scheduled sale ($521k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.83 | 12,500 | $260K | 50.0% |
| 2 | $20.83 | 12,500 | $260K | 50.0% |
| Total | $20.83 avg | 25,000 | $521K | 100% |
| Filing → |
| ELVN | SELL | 2025-09-30 | $74K | — | Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |